Biotechnology
Medical
Biopharmaceutical

CymaBay Therapeutics

$12.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CBAY and other stocks, options, ETFs, and crypto commission-free!

About

CymaBay Therapeutics Inc. Common Stock, also called CymaBay Therapeutics, is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Read More Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Employees
43
Headquarters
Newark, California
Founded
1988
Market Cap
886.15M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
694.89K
High Today
$13.01
Low Today
$12.64
Open Price
$13.00
Volume
893.88K
52 Week High
$15.00
52 Week Low
$6.31

Collections

Biotechnology
Medical
Biopharmaceutical
Therapy
Research And Development
Health
Pharmaceutical
Technology

News

Yahoo FinanceMay 9

Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc

Does CymaBay Therapeutics Inc (NASDAQ:CBAY) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to generate millions in profits each year. It is also true that some hedge fund players fail inconceivably on some occasions, but net net th...

113
Seeking AlphaMay 9

CymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q1 2019 Results - Earnings Call Transcript

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Dan Menold – Vice President of Finance Sujal Shah – Chief Executive Officer Chuck McWherter – Chief Scientific Officer Pol Boudes – Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Roth Capital Partners Ellie Merle – Cantor Fitzgerald Mike Kratky – SVB Leerink Steve Seedhouse – Raymond James Jay Olson – Oppenheimer Ed Arce – H.C. Wainwright Jeffrey – w...

56
Yahoo FinanceMay 2

Genfit, Cymbay Hope to Crack Large Liver Disease Market

- By Barry Cohen Investors seeking to find the next great pharmaceutical company may want to concentrate on emerging biopharma. The smaller members of the group are driving growth in research. Moreover, they have less need for a partner or to be acquired to develop their drugs, according to a report by health care research firm IQVIA (IQVA). About two of every three patents on drugs launched last year were awarded to emerging biopharmas . According to the report, they also accounted for nearly the...

93

Earnings

-$0.37
-$0.28
-$0.20
-$0.11
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.